High on-treatment platelet reactivity in peripheral arterial disease: A systematic review.
Lauren N GoncalvesVeerle van VelzeFrederikus A KlokPim GalRimke C VosJaap F HammingKoen E A van der BogtPublished in: Vascular (2023)
No consensus on technique or cut-off values for HTPR testing has been reached. Patients with HTPR are potentially at a greater risk of adverse limb-related and cardiovascular events than patients sensitive to antiplatelet therapy illustrating the need for clinical implementation of HTPR testing. Future research must aim for consistent methodology. Adaptation of antiplatelet therapy based on HTPR results requires further exploration.
Keyphrases
- antiplatelet therapy
- cardiovascular events
- percutaneous coronary intervention
- acute coronary syndrome
- coronary artery disease
- end stage renal disease
- ejection fraction
- primary care
- newly diagnosed
- cardiovascular disease
- healthcare
- peritoneal dialysis
- emergency department
- type diabetes
- current status
- atrial fibrillation
- drug induced